The plasma concentrations of 5-HT in Group T was lower than Group C at T<sub>1</sub> (348.54 ± 138.49 vs. 418.69 ± 124.68, P = 0.03), T<sub>2</sub> (324.28 ± 112.73 vs. 398.52 ± 114.53, P < 0.01), T<sub>4</sub> (309.64 ± 129.09 vs. 388.46 ± 115.36, P = 0.04) postoperatively and concentrations of SP at T<sub>1</sub> (59.38 ± 24.68 vs. 78.93 ± 26.32, P < 0.01), T<sub>2</sub> (49.36 ± 25.55 vs. 66.49 ± 23.57, P = 0.02), T<sub>3</sub> (42.19 ± 24.36 vs. 64.15 ± 28.16, P = 0.04), T<sub>4</sub> (39.26 ± 19.88 vs. 54.64 ± 20.62, P = 0.02) postoperatively were also lower than Group C. Meanwhile, the occurrences of vertigo (6.7 vs. 18.3%, P < 0.01), nausea and vomiting (11.7 vs. 21.7%, P < 0.01), constipation (10.0 vs. 20.0%, P = 0.03) in Group T were also lower.
Aprepitant (APT), an antiemetic drug belonging to the class of substance P antagonists is efficiently used in both acute and delayed chemotherapy-induced nausea and vomiting.
As a combination of a neurokinin-1 (NK<sub>1</sub>) receptor antagonist (RA) and 5-HT<sub>3</sub>RA, NEPA offers 5-day chemotherapy-induced nausea and vomiting prevention with a single dose and an opportunity to improve adherence to antiemetic guidelines.
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.